Go to the list of all blogs
Allana's Avatar
published in Blogs
Aug 26, 2026
Why Is Spyre Therapeutics (SYRE) Stock Down -13.8% Today?

Why Is Spyre Therapeutics (SYRE) Stock Down -13.8% Today?

Key Takeaways

  • Shares fell about 13.8%, trading near $92.54 after closing the prior session at $107.36.
  • The primary catalyst was a Phase 2 readout for SPY072 in rheumatoid arthritis that fell short of the company's internal bar for monotherapy development.
  • Spyre will not advance SPY072 as a standalone RA treatment, but will keep exploring it in combination approaches.
  • Analysts largely retained Buy/Outperform ratings, though several trimmed price targets.
  • Traders are now focused on upcoming readouts in psoriatic arthritis, axial spondyloarthritis, and ulcerative colitis.

Opening Summary

Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotechnology company developing long-acting antibodies for inflammatory bowel disease (IBD) and other immune-mediated conditions, saw its shares slide sharply on Tuesday. The stock dropped roughly 13.8%, changing hands near $92.54 versus a prior close of $107.36. The move was driven by a single clinical catalyst: topline data from the rheumatoid arthritis (RA) arm of the company's SKYWAY Phase 2 trial, which investors judged insufficient to justify continued development of SPY072 as a standalone therapy.

SPY072 Misses the Bar in Rheumatoid Arthritis

The day's selloff stemmed from disappointing Phase 2 results for SPY072, an investigational anti-TL1A antibody, in rheumatoid arthritis. Both tested doses beat placebo and showed statistically meaningful improvements on key endpoints, but the overall effect size failed to clear the strict internal performance threshold Spyre had set to prioritize monotherapy development.

In the data, the low-dose arm posted a change from baseline in DAS28-CRP of -1.9 compared with -1.3 for placebo at week 12, while the high dose delivered a 63% ACR20 response rate versus 43% for placebo. Safety was generally clean, with adverse events reported in 27% of SPY072 participants versus 36% on placebo, most of which were mild or moderate. Still, management concluded the drug's competitive profile was not strong enough to justify a solo RA program, and the company said it will not pursue SPY072 as a monotherapy in RA.

Market Reaction and Analyst Response

The market reaction was immediate and decisive, as investors stripped out much of the value previously attributed to SPY072's RA opportunity. The stock opened near its recent highs before reversing lower through the session, reflecting disappointment that a program once seen as a potential value driver would no longer advance as a standalone treatment.

Wall Street's response was comparatively measured. Several firms reiterated bullish ratings while trimming price targets — Wedbush cut its target to $123 from $130 and BTIG to $121 from $132 — arguing that the setback does not undermine the company's core IBD combination strategy. Analysts generally framed the decline as an attractive entry point given the dense clinical calendar ahead, while acknowledging that the RA-related portion of the valuation has been largely removed from the stock.

Market Context and Trading Activity

Tuesday's decline was company-specific rather than a reflection of broad sector weakness, with the move driven almost entirely by the clinical update. Trading activity picked up meaningfully as investors repositioned around the news, and the shares retreated from levels just below their 52-week high. The pullback pushed SYRE back toward support near its recent moving averages, although the stock remains substantially higher over the past year after a prolonged rally fueled by positive ulcerative colitis data.

What Comes Next for SYRE

Despite the RA disappointment, Spyre retains a catalyst-rich pipeline. The company still expects Phase 2 readouts for SPY072 in psoriatic arthritis and axial spondyloarthritis in the fourth quarter of 2026, along with additional ulcerative colitis data from its SKYLINE platform trial. It is also exploring SPY072 in combination settings, including the SPY772 program pairing the antibody with an IL-17A/F inhibitor for hidradenitis suppurativa.

Key risks remain: Spyre is a clinical-stage company with no approved products or commercial revenue, and its valuation leaves limited room for further clinical missteps. Investors will closely watch whether upcoming readouts validate the company's broader thesis that its antibody combinations can differentiate in IBD and related autoimmune diseases.

Trending AI Robots

Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing traders to explore automated approaches matched to their own goals. Explore the Trending AI Robots page to see which strategies are currently leading the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SYRE

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


SYRE in downward trend: price dove below 50-day moving average on August 26, 2026

SYRE moved below its 50-day moving average on August 26, 2026 date and that indicates a change from an upward trend to a downward trend. In 41 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 57 cases where SYRE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.

The 10-day moving average for SYRE crossed bearishly below the 50-day moving average on September 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SYRE's RSI Oscillator exited the oversold zone, 32 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Momentum Indicator moved above the 0 level on September 14, 2026. You may want to consider a long position or call options on SYRE as a result. In 66 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on September 17, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 37 of 40 cases over the following month. The odds of a continued upward trend are 90%.

Following a +1.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 255 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 157 of 168 cases where SYRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.333) is normal, around the industry mean (25.951). P/E Ratio (1.716) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (436.793).

The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 58 to 128.84B. VRTX holds the highest valuation in this group at 128.84B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 5%. PDSB experienced the highest price growth at 112%, while LGVN experienced the biggest fall at -65%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -5%. For the same stocks of the Industry, the average monthly volume growth was -35% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
SYRE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company

Industry Biotechnology

Profile
Details
Industry
Pharmaceuticals Major
Address
221 Crescent Street
Phone
+1 617 651-5940
Employees
102
Web
https://www.spyre.com
Interact to see
Advertisement
A jump in the Producer Price Index from 0.3% to around 0.7% month‑over‑month signals that wholesale inflation is re‑accelerating, delaying Fed rate‑cut hopes and reviving the “higher for longer” rates narrative.business. Likely winners in this environment include energy and commodity producers (XOM, CVX, TTE, COP), inflation‑resilient financials (JPM, BAC), and real‑asset plays like pipelines and infrastructure, which can pass through higher prices; ETFs like XLE, XOP, XLF, DBA, GLD offer diversified exposure.
BGSI fell more than 11% today, pulling back from recent levels around the high‑$150s as investors reassessed the risk‑reward following the Q4 2025 print and major U.S. expansion plans. Full‑year 2025 sales rose 2.4% to US$3.14 billion, but same‑store sales declined 0.2%, while reported net earnings fell 25% to US$18.4 million due to US$22.6 million in acquisition and transformation costs.
NG shares fell over 11% today, giving back a portion of steep gains that had taken the stock from near US$2.30 a year ago to recent highs around US$14.40 before the latest pullback. The decline follows a cluster of Donlin‑related announcements — including selection of Fluor as Bankable Feasibility Study (BFS) contractor and an infrastructure/energy letter of intent — which, while positive, highlighted the scale, cost and timeline of the project rather than near‑term cash generation.
SA dropped over 9% today, sliding from around US$30–31 toward the high‑US$27 range in morning trading, as recent optimism about a near‑term KSM partnership met renewed focus on execution and valuation risk. Recent analysis has highlighted that Seabridge’s 2026 “report card” allocates 55% of management’s performance weighting to KSM‑related goals, with securing a JV partner given the single largest weight at 30%, underscoring how concentrated the investment thesis has become.
CABO shares fell over 11% today, sliding from the low‑US$110s toward the US$100 area, extending a brutal 12‑month decline of roughly 55% and bringing the stock closer to the bottom of its 52‑week range near US$70. Q4 2025 results showed a 6.1% year‑over‑year revenue drop to US$363.7 million, with residential data revenue down 4.2% and business data off 1.3%; full‑year revenue fell to about US$1.5 billion from US$1.6 billion in 2024.
In a market rattled by geopolitical tension, tariff uncertainty, and Fed rate volatility, one category of stocks continues to electrify traders: penny stocks, microcaps, and small-caps. These sub-$5 shares can surge 50%, 100%, or even 150% in a single session on a news catalyst — but without the right tools, most retail traders get caught on the wrong side. Enter Tickeron's two powerhouse AI robots: the Small-Cap Stocks - AI Trend Trader 60min (FA) and the Penny Stock - MicroCap Signal Bot 60min (FA).
Elite Returns in a Volatile Sector — Both robots delivered annualized returns above 94%, outperforming the vast majority of active semiconductor funds. High Consistency — Win rates of 68–71% mean these robots win more often than they lose — a rare edge in a sector famous for violent swings.
Exceptional Returns: +79.13% annualized return on a starting balance of $8,040.74, demonstrating consistent alpha generation in the comms-tech sector. High Win Rate: 59.43% of trades close in profit, with a Profit Factor of 2.65 — meaning every $1 risked historically returns $2.65.
Tight Risk Management — The 3% TP / 2% SL corridor keeps risk-reward structured and disciplined, cutting losses quickly while locking in gains before reversals. Right Tickers, Right Time — XOM, CVX, and COP are all up roughly 30% year-to-date in 2026, making them among the most high-momentum, liquid energy plays in the market right now.
AngloGold Ashanti (AU) shares are tumbling approximately 11% in premarket trading on March 19, 2026, extending a steep multi-week correction that has now erased more than 35% of the stock's value from its March 2 peak of $129.14. The primary sustained catalyst driving the decline is AngloGold's lowered 2026 production guidance, projecting gold output of 2.80–3.17 million ounces — a mid-point decline versus the company's 2025 output of approximately 3.1 million ounces, and below analyst expectations.
CSIQ shares tumbled approximately 18% in premarket trading on March 19, 2026, following the release of deeply disappointing Q4 2025 earnings before the open. The company reported a net loss of $1.66 per diluted share, far worse than the Wall Street consensus estimate of -$0.98, representing a 69% earnings miss.
YRD shares are tumbling approximately 17% in premarket trading on March 19, 2026, from a prior close of $3.68 to approximately $3.05, following the company's release of Q4 and full-year 2025 financial results before the U.S. market open. Primary catalyst: A dramatic swing to net loss in Q4 2025. Yiren Digital reported a Q4 net loss of RMB 882.2 million (~USD 126.1 million), compared to net income of RMB 331.4 million in Q4 2024 — a more than $250 million deterioration year-over-year.
Shares of MU are down approximately 6.66% in premarket trading on March 19, 2026, sliding from a prior close of $461.73 to around $431.00. Despite a historic earnings beat — fiscal Q2 2026 revenue of $23.86 billion versus the $19.19 billion consensus, and adjusted EPS of $12.20 against an $8.79 estimate — the stock is experiencing a classic "sell the news" reaction.
NEM is trading approximately 9% lower in Thursday premarket, extending Wednesday's 4.56% session loss, as gold prices collapse following the Federal Reserve's hawkish policy hold. Gold spot prices fell 4.21% to $4,616.42 per ounce on March 19, marking the precious metal's sixth straight session of declines — its longest losing streak since late 2024.
Shares of VG are surging approximately +8% in Thursday's premarket session on March 19, 2026, with the stock trading near $16.04, up from the March 18 closing price of $14.85. The primary catalyst is a continuation of bullish momentum driven by a series of analyst price target upgrades, with Scotiabank most recently raising its target from $9 to $11.
LINC shares surged approximately +16% in premarket trading on March 19, 2026, reaching roughly $45.83 from a prior close of $39.51. Primary catalyst: Lincoln Educational Services is hosting its highly anticipated Investor Day today at its brand-new Nashville, TN campus, with presentations beginning at 10:00 am CT (11:00 am ET), live-streamed to investors globally.
PSLV is trading approximately 12% lower in premarket on March 19, 2026, tracking a violent selloff in silver futures. The Federal Reserve's hawkish hold on March 18 — keeping rates at 3.50%–3.75% while signaling fewer cuts ahead — was the primary macro trigger.
The Fed kept rates at 3.5–3.75% and signaled a “higher for longer” stance, with no urgency to cut and a willingness to tighten again if inflation stalls. This backdrop tends to favor quality growth, financials, energy, industrials, and health care, while pressuring long‑duration, leveraged sectors like speculative tech, small caps, utilities, and REITs.
PICS shares fell over 20% today, reversing much of their post‑IPO bounce and dropping well below the US$19 IPO price after initially trading in the mid‑US$15–16 range. The selloff followed PicPay’s Q4 and full‑year 2025 results, which showed strong revenue growth but highlighted thin margins, intense competition and ongoing execution risk in credit underwriting and payments.
RCAT shares fell over 16% today, dropping from recent levels near US$17 toward the mid‑US$14–15 range, after trading as high as US$18.78 in the past year and more than tripling from a 52‑week low of US$4.60.